Cardiac amyloidosis: Advancements in diagnosis, investigation and management

Cardiac amyloidosis, once regarded as a rare and elusive cause of heart failure, has rapidly emerged as a critical diagnosis among patients presenting with unexplained left ventricular hypertrophy, diastolic dysfunction, and heart failure with preserved ejection fraction. Advances in non-invasive diagnostic algorithms, sophisticated imaging modalities including echocardiographic strain analysis and cardiac MRI with T1 mapping, as well as the availability of targeted disease-modifying treatments, have revolutionized the approach to both transthyretin (ATTR) and light-chain (AL) amyloidosis. Despite these notable improvements, key challenges persist: delayed diagnosis, underrecognized disease in diverse populations, and the complexity of individualized therapy, all of which pose significant barriers to optimal patient outcomes and quality of life.This Research Topic aims to consolidate and highlight the most recent developments in the detection, investigation, and management of cardiac amyloidosis across the disease continuum. The primary goal is to foster a deeper understanding of the epidemiology, red flags, and diagnostic nuances by integrating recent findings in multimodality imaging, biomarker profiling, and molecular typing. The collection encourages exploration of both hereditary and acquired forms of amyloidosis, the implications of genotype–phenotype correlations, evolving therapeutic algorithms, and efforts to improve patient stratification, follow-up, and care pathways. Together, these advances have the potential to support earlier recognition and more comprehensive, patient-centered strategies driven by multidisciplinary care teams.To gather further insights into the multifaceted landscape of cardiac amyloidosis, we welcome articles addressing, but not limited to, the following themes:Epidemiology and clinical red flags: Understanding prevalence, screening, and early recognition in various populationsEmergent diagnostic strategies: Multimodality imaging (echocardiography, strain, cardiac MRI, bone scintigraphy, PET), biomarkers, biopsy, and advanced typing using mass spectrometryGenetics and disease subtypes: Hereditary and wild-type ATTR, AL amyloidosis, rare subtypes, and implications for family screeningTherapeutic innovations: Use of TTR stabilizers, gene silencers, degraders, plasma cell–directed therapies, transplantation, and mechanical support; integrated multidisciplinary carePrognosis and outcomes: Risk stratification, treatment response metrics, long-term follow-up, and patient-reported quality of lifeFuture directions: Novel imaging agents, artificial intelligence–assisted diagnostics, digital monitoring solutions, and new therapeutic targetsAll article types are encouraged in this topic. The overarching aim is to accelerate earlier diagnosis, improve risk assessment, and advance multidisciplinary management—enhancing survival and quality of life for patients with cardiac amyloidosis. Topic editors: Rachel Anne Xuereb, Nicola Mumoli Source: https://www.frontiersin.org/research-topics/77632/cardiac-amyloidosis-advancements-in-diagnosis-investigation-and-management